226950 — OliX Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- KR₩247bn
- KR₩261bn
- KR₩17bn
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,130 | 2,474 | 3,674 | 9,320 | 17,064 |
Cost of Revenue | |||||
Gross Profit | 1,111 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 16,247 | 18,716 | 27,614 | 31,696 | 34,828 |
Operating Profit | -15,117 | -16,241 | -23,939 | -22,376 | -17,764 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14,244 | -20,511 | -29,997 | -29,108 | -18,170 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14,353 | -19,385 | -29,176 | -28,113 | -19,102 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -14,353 | -19,385 | -29,715 | -19,495 | -19,102 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -14,353 | -19,385 | -29,715 | -19,495 | -19,102 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,102 | -1,474 | -2,099 | -1,878 | -1,339 |
Dividends per Share |